Wholomics, a startup founded by researchers from Dana Farber and University College London, unveiled promising data on its metabolomic platform's ability to detect diverse tumor types from serum samples. The approach identifies metabolic and lipidomic changes induced by cancer and tumor microenvironment interactions using nuclear magnetic resonance, distinguishing it from DNA-based methods. Early retrospective studies showed sensitivity across colorectal, lung, pancreatic, breast, and other cancers, positioning this technology as a novel multi-cancer early detection tool.